MedPath

Phase II Study of Fluconazole for Lymphocutaneous and Visceral Sporotrichosis

Phase 2
Completed
Conditions
Sporotrichosis
Registration Number
NCT00004938
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Brief Summary

OBJECTIVE:

I. Evaluate the efficacy of fluconazole in patients with lymphocutaneous or visceral sporotrichosis.

Detailed Description

PROTOCOL OUTLINE:

Patients are treated with daily oral fluconazole for up to 24 months. Follow-up continues for at least 1 year.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
30
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath